Cargando…
Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels
OBJECTIVE: Achieving an early molecular response (EMR) is crucial for improving the prognosis of patients with chronic myeloid leukemia (CML). The halving time (HT) and reduction ratio (RR) of BCR::ABL1 transcript levels have recently emerged as additional prognostic indexes besides the BCR::ABL1 In...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421336/ https://www.ncbi.nlm.nih.gov/pubmed/35620443 http://dx.doi.org/10.4274/tjh.galenos.2022.2022-0024 |
_version_ | 1784777569377189888 |
---|---|
author | Ceran, Funda Akıncı, Sema Uçar, Mehmet Ali Korkmaz, Gülten Gündüz, Mehmet Çavdarlı, Büşranur Bakanay, Şule Mine Falay, Mesude Dağdaş, Simten Dilek, İmdat Özet, Gülsüm |
author_facet | Ceran, Funda Akıncı, Sema Uçar, Mehmet Ali Korkmaz, Gülten Gündüz, Mehmet Çavdarlı, Büşranur Bakanay, Şule Mine Falay, Mesude Dağdaş, Simten Dilek, İmdat Özet, Gülsüm |
author_sort | Ceran, Funda |
collection | PubMed |
description | OBJECTIVE: Achieving an early molecular response (EMR) is crucial for improving the prognosis of patients with chronic myeloid leukemia (CML). The halving time (HT) and reduction ratio (RR) of BCR::ABL1 transcript levels have recently emerged as additional prognostic indexes besides the BCR::ABL1 International Scale (IS). We aimed to investigate the prognostic role of BCR::ABL1 transcript levels, HT, and RR on molecular response kinetics at 3 months in patients with newly diagnosed chronic-phase (CP)-CML. MATERIALS AND METHODS: Forty patients with CP-CML who received first-line imatinib treatment were included in this study. BCR::ABL1 transcript levels and molecular responses at baseline and at 3, 6, 12, and 24 months of treatment were evaluated retrospectively. Major molecular response (MMR) at 12 months and event-free survival (EFS) were determined as primary endpoints and the effects of treatment kinetics on these parameters were examined. RESULTS: Of the 40 patients, BCR::ABL1 IS was ≤10% at 3 months in 72.5%, representing EMR. The rate of event occurrence was 45.5% in patients with BCR::ABL1 IS of >10%, whereas it was 6.9% in those with BCR::ABL1 IS of ≤10% (p=0.004). MMR was detected in 62.1% of the patients with EMR and in 9.1% of those without EMR (p=0.003). The cut-off value for achieving MMR was 24 days for HT and 0.04 for RR. Deep molecular response (DMR) at 24 months was associated with HT of ≤24 days and RR of ≤0.04. EFS was found to be significantly better in the group with BCR::ABL1 IS of ≤10% and HT of ≤24 days (p=0.001) and in the group with BCR::ABL1 IS of ≤10% and RR of ≤0.04 (p=0.007) compared to others. CONCLUSION: Our findings revealed that MMR could be predicted via EMR as well as by HT and RR. Additionally, HT of ≤24 days and RR of ≤0.04 were more important thanBCR::ABL1 IS of ≤10% in achieving DMR at 24 months, and the combination of BCR::ABL1 IS of ≤10% with both HT of ≤24 days and RR of ≤0.04 has the best predictive value for EFS. |
format | Online Article Text |
id | pubmed-9421336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-94213362022-09-07 Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels Ceran, Funda Akıncı, Sema Uçar, Mehmet Ali Korkmaz, Gülten Gündüz, Mehmet Çavdarlı, Büşranur Bakanay, Şule Mine Falay, Mesude Dağdaş, Simten Dilek, İmdat Özet, Gülsüm Turk J Haematol Research Article OBJECTIVE: Achieving an early molecular response (EMR) is crucial for improving the prognosis of patients with chronic myeloid leukemia (CML). The halving time (HT) and reduction ratio (RR) of BCR::ABL1 transcript levels have recently emerged as additional prognostic indexes besides the BCR::ABL1 International Scale (IS). We aimed to investigate the prognostic role of BCR::ABL1 transcript levels, HT, and RR on molecular response kinetics at 3 months in patients with newly diagnosed chronic-phase (CP)-CML. MATERIALS AND METHODS: Forty patients with CP-CML who received first-line imatinib treatment were included in this study. BCR::ABL1 transcript levels and molecular responses at baseline and at 3, 6, 12, and 24 months of treatment were evaluated retrospectively. Major molecular response (MMR) at 12 months and event-free survival (EFS) were determined as primary endpoints and the effects of treatment kinetics on these parameters were examined. RESULTS: Of the 40 patients, BCR::ABL1 IS was ≤10% at 3 months in 72.5%, representing EMR. The rate of event occurrence was 45.5% in patients with BCR::ABL1 IS of >10%, whereas it was 6.9% in those with BCR::ABL1 IS of ≤10% (p=0.004). MMR was detected in 62.1% of the patients with EMR and in 9.1% of those without EMR (p=0.003). The cut-off value for achieving MMR was 24 days for HT and 0.04 for RR. Deep molecular response (DMR) at 24 months was associated with HT of ≤24 days and RR of ≤0.04. EFS was found to be significantly better in the group with BCR::ABL1 IS of ≤10% and HT of ≤24 days (p=0.001) and in the group with BCR::ABL1 IS of ≤10% and RR of ≤0.04 (p=0.007) compared to others. CONCLUSION: Our findings revealed that MMR could be predicted via EMR as well as by HT and RR. Additionally, HT of ≤24 days and RR of ≤0.04 were more important thanBCR::ABL1 IS of ≤10% in achieving DMR at 24 months, and the combination of BCR::ABL1 IS of ≤10% with both HT of ≤24 days and RR of ≤0.04 has the best predictive value for EFS. Galenos Publishing 2022-09 2022-08-25 /pmc/articles/PMC9421336/ /pubmed/35620443 http://dx.doi.org/10.4274/tjh.galenos.2022.2022-0024 Text en © Copyright 2022 by Turkish Society of Hematology / Turkish Journal of Hematology, Published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ceran, Funda Akıncı, Sema Uçar, Mehmet Ali Korkmaz, Gülten Gündüz, Mehmet Çavdarlı, Büşranur Bakanay, Şule Mine Falay, Mesude Dağdaş, Simten Dilek, İmdat Özet, Gülsüm Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels |
title | Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels |
title_full | Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels |
title_fullStr | Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels |
title_full_unstemmed | Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels |
title_short | Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels |
title_sort | predictive factors for molecular response in chronic myeloid leukemia: reduction ratio and halving time of bcr::abl1 is transcript levels |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421336/ https://www.ncbi.nlm.nih.gov/pubmed/35620443 http://dx.doi.org/10.4274/tjh.galenos.2022.2022-0024 |
work_keys_str_mv | AT ceranfunda predictivefactorsformolecularresponseinchronicmyeloidleukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT akıncısema predictivefactorsformolecularresponseinchronicmyeloidleukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT ucarmehmetali predictivefactorsformolecularresponseinchronicmyeloidleukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT korkmazgulten predictivefactorsformolecularresponseinchronicmyeloidleukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT gunduzmehmet predictivefactorsformolecularresponseinchronicmyeloidleukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT cavdarlıbusranur predictivefactorsformolecularresponseinchronicmyeloidleukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT bakanaysulemine predictivefactorsformolecularresponseinchronicmyeloidleukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT falaymesude predictivefactorsformolecularresponseinchronicmyeloidleukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT dagdassimten predictivefactorsformolecularresponseinchronicmyeloidleukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT dilekimdat predictivefactorsformolecularresponseinchronicmyeloidleukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT ozetgulsum predictivefactorsformolecularresponseinchronicmyeloidleukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels |